THTX

THTX

USD

Theratechnologies Inc. Common Shares

$2.770-0.020 (-0.717%)

即時價格

Healthcare
生物科技
加拿大

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$2.790

最高

$2.900

最低

$2.725

交易量

0.04M

公司基本面

市值

129.6M

行業

生物科技

國家

Canada

交易統計

平均交易量

3.06M

交易所

NCM

貨幣

USD

52週範圍

最低 $1.08當前 $2.770最高 $3.13

相關新聞

GlobeNewswire

Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced that following careful

查看更多
Theratechnologies Provides Update on Sale Process
BusinessWire

Soleus Capital Issues Letter to The Board of Theratechnologies

Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ:THTX) (the "Company"), today sent a letter to the Board of

查看更多
Soleus Capital Issues Letter to The Board of Theratechnologies
GlobeNewswire

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in

查看更多
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
BusinessWire

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

Future Pak, LLC ("Future Pak") today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. ("Theratechnologies") (NASDAQ:THTX).

查看更多
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
GlobeNewswire

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval

查看更多
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report